These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19734850)

  • 21. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.
    Bartlett JM; Thomas J; Ross DT; Seitz RS; Ring BZ; Beck RA; Pedersen HC; Munro A; Kunkler IH; Campbell FM; Jack W; Kerr GR; Johnstone L; Cameron DA; Chetty U
    Breast Cancer Res; 2010; 12(4):R47. PubMed ID: 20615243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
    Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
    Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
    Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
    J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.
    Boman K; Segersten U; Ahlgren G; Eberhard J; Uhlén M; Jirström K; Malmström PU
    BMC Urol; 2013 Apr; 13():17. PubMed ID: 23565664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
    Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
    Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
    Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.
    Magnusson K; Gremel G; Rydén L; Pontén V; Uhlén M; Dimberg A; Jirström K; Pontén F
    BMC Cancer; 2016 Nov; 16(1):904. PubMed ID: 27863473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
    Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
    Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.
    DeCensi A; Guerrieri-Gonzaga A; Gandini S; Serrano D; Cazzaniga M; Mora S; Johansson H; Lien EA; Pruneri G; Viale G; Bonanni B
    Ann Oncol; 2011 Mar; 22(3):582-587. PubMed ID: 20716629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.
    McGovern SL; Qi Y; Pusztai L; Symmans WF; Buchholz TA
    Breast Cancer Res; 2012 May; 14(3):R72. PubMed ID: 22559056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of RNA-Binding Motif 3 (RBM3) Protein Levels and Nuclear Architecture Changes in Aggressive and Recurrent Prostate Cancer.
    Carleton NM; Zhu G; Miller MC; Davis C; Kulkarni P; Veltri RW
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1237. PubMed ID: 32587951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
    Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
    J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
    J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.
    Lehn S; Tobin NP; Sims AH; Stål O; Jirström K; Axelson H; Landberg G
    BMC Cancer; 2014 Feb; 14():119. PubMed ID: 24559095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.
    Dahl E; En-Nia A; Wiesmann F; Krings R; Djudjaj S; Breuer E; Fuchs T; Wild PJ; Hartmann A; Dunn SE; Mertens PR
    BMC Cancer; 2009 Nov; 9():410. PubMed ID: 19930682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
    Esserman LJ; Yau C; Thompson CK; van 't Veer LJ; Borowsky AD; Hoadley KA; Tobin NP; Nordenskjöld B; Fornander T; Stål O; Benz CC; Lindström LS
    JAMA Oncol; 2017 Nov; 3(11):1503-1510. PubMed ID: 28662222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer.
    Holm J; Yu NY; Johansson A; Ploner A; Hall P; Lindström LS; Czene K
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.
    Castellano I; Allia E; Accortanzo V; Vandone AM; Chiusa L; Arisio R; Durando A; Donadio M; Bussolati G; Coates AS; Viale G; Sapino A
    Breast Cancer Res Treat; 2010 Dec; 124(3):607-17. PubMed ID: 20127405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen.
    Göthlin Eremo A; Tina E; Wegman P; Stål O; Fransén K; Fornander T; Wingren S
    Int J Oncol; 2015 Oct; 47(4):1311-20. PubMed ID: 26238412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.